Literature DB >> 17406220

Radiolabeling of HYNIC-annexin V with technetium-99m for in vivo imaging of apoptosis.

Francis G Blankenberg1, Jean-Luc Vanderheyden, H William Strauss, Jonathan F Tait.   

Abstract

Apoptosis is a critical factor in AIDS and other viral illnesses, cerebral and myocardial ischemia, autoimmune and neurodegenerative states, organ and bone marrow transplant rejection, and tumor response to chemotherapy and radiation. Improved methods to identify sites of apoptosis are increasing our understanding of the pathophysiology and treatment of these and numerous other human disorders. Here we describe the most used method for labeling annexin V, a protein with a high affinity for apoptotic cells in vitro, with technetium-99m (99mTc) as a radionuclide imaging agent that can localize and non-invasively quantify apoptosis in vivo when coupled with single-photon emission tomography. In this method, annexin V is first attached to the bifunctional chelator molecule hydrazino nicotinate (HYNIC). Once prepared, HYNIC-annexin V can be labeled with 99mTc, a widely available gamma-radiation-emitting radionuclide, for intravenous injection in as little as 30 min without the need for specialized reagents or equipment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17406220     DOI: 10.1038/nprot.2006.17

Source DB:  PubMed          Journal:  Nat Protoc        ISSN: 1750-2799            Impact factor:   13.491


  16 in total

1.  In vivo imaging of drug-induced mitochondrial outer membrane permeabilization at single-cell resolution.

Authors:  Sarah Earley; Claudio Vinegoni; Joshua Dunham; Rostic Gorbatov; Paolo Fumene Feruglio; Ralph Weissleder
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

Review 2.  In vivo imaging in cancer.

Authors:  John Condeelis; Ralph Weissleder
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-09-22       Impact factor: 10.005

Review 3.  Nuclear imaging of molecular processes in cancer.

Authors:  Rafael Torres Martin de Rosales; Erik Arstad; Philip J Blower
Journal:  Target Oncol       Date:  2009-09-25       Impact factor: 4.493

4.  Monitoring apoptosis and neuronal degeneration by real-time detection of phosphatidylserine externalization using a polarity-sensitive indicator of viability and apoptosis.

Authors:  Yujin E Kim; Jeannie Chen; Ralf Langen; Jonah R Chan
Journal:  Nat Protoc       Date:  2010-07-08       Impact factor: 13.491

5.  A Systematic Comparison of 18F-C-SNAT to Established Radiotracer Imaging Agents for the Detection of Tumor Response to Treatment.

Authors:  Timothy H Witney; Aileen Hoehne; Robert E Reeves; Ohad Ilovich; Mohammad Namavari; Bin Shen; Frederick T Chin; Jianghong Rao; Sanjiv S Gambhir
Journal:  Clin Cancer Res       Date:  2015-05-13       Impact factor: 12.531

6.  Cardioprotective Effects of HSP72 Administration on Ischemia-Reperfusion Injury.

Authors:  Takashi Tanimoto; Missag H Parseghian; Takehiro Nakahara; Hideki Kawai; Navneet Narula; Dongbin Kim; Robert Nishimura; Richard H Weisbart; Grace Chan; Richard A Richieri; Nezam Haider; Farhan Chaudhry; Glenn T Reynolds; John Billimek; Francis G Blankenberg; Partho P Sengupta; Artiom D Petrov; Takashi Akasaka; H William Strauss; Jagat Narula
Journal:  J Am Coll Cardiol       Date:  2017-09-19       Impact factor: 24.094

Review 7.  Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research.

Authors:  Alesia Ivashkevich; Christophe E Redon; Asako J Nakamura; Roger F Martin; Olga A Martin
Journal:  Cancer Lett       Date:  2011-12-21       Impact factor: 8.679

Review 8.  Imaging in the era of molecular oncology.

Authors:  Ralph Weissleder; Mikael J Pittet
Journal:  Nature       Date:  2008-04-03       Impact factor: 49.962

9.  A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells.

Authors:  Matthew R Hight; Yiu-Yin Cheung; Michael L Nickels; Eric S Dawson; Ping Zhao; Samir Saleh; Jason R Buck; Dewei Tang; M Kay Washington; Robert J Coffey; H Charles Manning
Journal:  Clin Cancer Res       Date:  2014-02-26       Impact factor: 12.531

10.  Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer.

Authors:  Chirayu Shah; Todd W Miller; Shelby K Wyatt; Eliot T McKinley; Maria Graciela Olivares; Violeta Sanchez; Donald D Nolting; Jason R Buck; Ping Zhao; M Sib Ansari; Ronald M Baldwin; John C Gore; Rachel Schiff; Carlos L Arteaga; H Charles Manning
Journal:  Clin Cancer Res       Date:  2009-07-07       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.